The Michael J. Fox Foundation for Parkinson's Research, New York, NY 10004, USA.
Sci Transl Med. 2011 Apr 20;3(79):79ps14. doi: 10.1126/scitranslmed.3002488.
Biomarkers for detecting the early stages of Parkinson's disease (PD) could accelerate development of new treatments. Such biomarkers could be used to identify individuals at risk for developing PD, to improve early diagnosis, to track disease progression with precision, and to test the efficacy of new treatments. Although some progress has been made, there are many challenges associated with developing biomarkers for detecting PD in its earliest stages.
用于检测帕金森病（PD）早期阶段的生物标志物可以加速新疗法的开发。这些生物标志物可以用于识别有发展为 PD 风险的个体，以改善早期诊断，精确跟踪疾病进展，并测试新疗法的疗效。尽管已经取得了一些进展，但在开发用于检测 PD 早期阶段的生物标志物方面仍存在许多挑战。
